Fig. 6
Inter-tumoral variation in levels of HDAC activity and expression emphasizes the need for patient stratification. a Graphs depict the HDAC activity in 38 human tumor tissue samples from 8 different tissues. HDAC activity is depicted as absorbance at 405 nm per mg of lysate. TSA indicates negative control consisting of HDAC inhibitor Trichostatin A. Numbers on the X-axis indicate sample number. b–d Graphs depict expression of HDAC1–3 analyzed from RNA-seq data available in TCGA for (b) normal versus breast cancer (c) breast cancer subtypes based on hormone classification and (d) normal versus pan-cancer. p value was determined using the Wilcoxon–Mann–Whitney test analysis. Error bars represent quartile range 25 and 75% respectively for all the samples. Dots represent outliers. BR—breast, BC–brain, BM–buccal mucosa, TN–tongue, K–kidney, L–liver, R–rectum and GB–gall bladder. $p values for HDAC1 (by one-way ANOVA) is < 0.0001 and by the Wilcoxon–Mann–Whitney test for individual groups ER + PR + Her- v/s ER-PR-Her+ is 0.0274, ER + PR + Her- v/s ER-PR-Her+  is 0.000191 and ER + PR + Her- v/s ER-PR-Her- is 0.000305. # p-values for HDAC2 (by one- way ANOVA) is < 0.0001 and by Wilcoxon–Mann–Whitney test for individual groups ER + PR + Her- v/s ER-PR-Her+ is 2.71 e-07, ER + PR + Her- v/s ER-PR-Her+ is 0.0485 and ER + PR + Her- v/s ER-PR-Her- is 1.85 e− 23. % p-values for HDAC3 (by one- way ANOVA) is 0.4797 and by Wilcoxon–Mann–Whitney test for individual groups ER + PR + Her- v/s ER-PR-Her+ is 0.591, ER + PR + Her- v/s ER-PR-Her+ is 0.738 and ER + PR + Her- v/s ER-PR-Her- is 0.231